YSOPIA -Model Yso5 -Discovery-Stage Program

Yso5 is a discovery-stage program leveraging a specific keystone gut bacteria (undisclosed) to potentiate the effects of Immune Checkpoint Blockade (ICB) drugs. The field of cancer therapy has been revolutionized by the use of immunotherapy. The microbiome breakthrough science today paves the way for innovative biotherapies to potentiate the effectiveness of these cancer immunotherapies. YSOPIA is exploring the role of specific keystone bacteria with high therapeutic potential in the oncology field based on a strong understanding of their mechanisms of action.